SEC Form 4 · accession 0001078782-17-000206
VOLITIONRX LTD · VNRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Bradley Terrell M.D.
Officer — Chief Medical Officer
Period of report
Feb 14, 2017
Accepted (ET)
Feb 15, 2017 · 1:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000093314
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy)F2,F3 | $2.47 | Feb 14, 2017 | D | 25,000 | D | — | — | Common Stock | 25,000 | 0 | D |
| Warrant (Right to Buy)F2,F3 | $2.47 | Feb 14, 2017 | A | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The replacement warrant amends the performance criteria for a vesting milestone.
- F2The date exercisable is variable and depends on the achievement of the performance criteria outlined in the warrant agreement, as amended.
- F3The subject warrant shall expire three years after the vesting date.